Expanding RAS-Targeted Franchise and Late-Stage Pipeline Drive Buy Rating on Revolution Medicines

Analyst Charles Zhu of LifeSci Capital maintained a Buy rating on Revolution Medicines, retaining the price target of $104.00.

Charles Zhu has given his Buy rating due to a combination of factors that underscore Revolution Medicines’ expanding clinical and strategic momentum. He highlights the company’s deepening commitment to pancreatic, lung, and colorectal cancers, evidenced by a broad Phase 3 program for the pan-RAS inhibitor daraxonrasib that spans first-line, second-line, and adjuvant pancreatic cancer as well as multiple non-small cell lung cancer settings. Management’s intent to aggressively advance zoldonrasib, including several pivotal trials planned for 2026 in first-line pancreatic cancer and lung cancer, further supports a robust late-stage pipeline with multiple shots on goal.

In addition, Zhu points to strategic plans for elironrasib in both front-line and later-line lung cancer combinations as a way to capture additional RAS-mutant patient segments and address resistance after prior therapies. He also views next-generation assets such as RM-055, designed to overcome resistance via an evolution of the company’s tri-complex platform, as important contributors to long-term value, with upcoming scientific disclosures serving as potential catalysts. Taken together with continuing business development optionality and a management team clearly focused on building a diversified RAS-targeted franchise across major solid tumors, these elements underpin his favorable risk–reward view and support the Buy rating.

In another report released yesterday, TipRanks – Google also initiated coverage with a Buy rating on the stock with a $136.00 price target.